Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

OK
skip to main content

Skin testing and dupilumab

Question:

8/26/2020
I was wondering if dupilumab affects skin prick and intradermal testing and if so, how best to evaluate a patient for allergic rhinitis as well as food allergy.

Answer:
I was unable to find a date in the literature regarding skin testing and the impact that dupilumab may or may not have on this procedure.

I asked Dr. Mitch Grayson to comment as well. "I'm not aware of any data regarding this. Anti-IL4/IL13 does not impair the degranulation of mast cells with allergen challenge, so assessing allergic sensitization by skin testing shouldn't be affected. It is theoretically possible for anti-IL4/IL13 to reduce IgE levels, and this could potentially lead to loss of sensitization. In this scenario, the drug would not lead to a false negative, as the test would be negative because the patient was no longer making IgE against the allergen."

I hope this is helpful,

Andrew Murphy, MD, FAAAAI